we 201 has been researched along with Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jose, A; Karnam, S; Ninave, KM; Venuganti, VVK | 1 |
| Boeing, H; Floegel, A; Johnson, T; Kaaks, R; Kühn, T; Otto, W; Rolle-Kampczyk, U; Sookthai, D; von Bergen, M | 1 |
2 other study(ies) available for we 201 and Breast Cancer
| Article | Year |
|---|---|
Temperature-sensitive liposomes for co-delivery of tamoxifen and imatinib for synergistic breast cancer treatment.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Compounding; Drug Liberation; Female; Humans; Imatinib Mesylate; Liposomes; Lysophosphatidylcholines; Nanoparticles; Tamoxifen; Temperature | 2019 |
Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics study.
Topics: Biomarkers, Tumor; Breast Neoplasms; Carnitine; Cohort Studies; Colorectal Neoplasms; Female; Humans; Lipid Metabolism; Lipids; Lysophosphatidylcholines; Male; Middle Aged; Neoplasms; Prospective Studies; Prostatic Neoplasms | 2016 |